[(2R,3R,4R,5R)-2-methoxy-1-oxo-4,5,6-triphosphonooxyhexan-3-yl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(2R,3R,4R,5R)-2-methoxy-1-oxo-4,5,6-triphosphonooxyhexan-3-yl] dihydrogen phosphate
• 化学式: C₇H₁₈O₁₈P₄
• 分子量: 514.1
• InChiKey: CHNLAUAFLDHMCT-BDVNFPICSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -7.3
• 重原子数：
  29
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  293
• 氢给体数：
  8
• 氢受体数：
  18

文献信息

• MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT
  申请人：NormOxys, Inc.

  公开号：EP2968617A1

  公开（公告）日：2016-01-20
• [EN] MYO-INOSITOL TRISPYROPHOSPHATE AS AN ANTI-OBESITY AGENT<br/>[FR] UTILISATION DU MYO-INOSITOL TRISPYROPHOSPHATE COMME AGENT ANTI-OBÉSITÉ
  申请人：NORMOXYS INC

  公开号：WO2014143939A1

  公开（公告）日：2014-09-18

  The present invention provides for novel treatments of obesity and overweight and related disorders. The invention provides, in part, method of treatment comprising, or uses of inositol-tripyrophosphate (ITPP) in these disease states. Obesity refers to the medical condition in which adipose tissue (body fat) is systemically accumulated as a result of, for example, energy intake that is higher than energy expenditure over a long period of time. Obesity may result in various associated diseases, such as arteriosclerosis.